SBI Securities’s Benitec Biopharma BNTC Stock Holding History

SBI Securities’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$14	–	4047
2025 Q3	$14	Buy	+1	New	+$13	﹤0.01%	3974

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SBI Securities's BNTC Position: Q4 2025 in Review

SBI Securities sold out of Benitec Biopharma (BNTC) in Q4 2025, closing a stake of 1 share — an estimated $14 sold.

SBI Securities first reported a position in BNTC in Q3 2025 and held it in 1 quarter. The position peaked at $14 in Q3 2025. 72 funds tracked by Wall St. Rank hold BNTC as of Q4 2025.

SBI Securities reported no remaining Benitec Biopharma position as of Q4 2025 after selling out during the quarter.
SBI Securities sold 1 Benitec Biopharma share in Q4 2025, an estimated $14.
SBI Securities first reported a position in Benitec Biopharma in Q3 2025 and held it in 1 quarter.
SBI Securities's Benitec Biopharma position peaked at $14 in Q3 2025.
72 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.